Opinion
Video
Approaching Treatment Sequencing In Heavily Pretreated Patients
Author(s):
Explore the importance of clinical trials for ovarian cancer treatments, highlighting innovative therapies and the need for early patient access.
Video content is prompted by the following:
Approaches to Treatment, Sequencing, and Heavily Pretreated Patients With Novel Agents
Key Discussion Points:
- Clinical Trial Access and Patient Referral
- Dr Moore emphasized the importance of seeking out clinical trials for platinum-resistant patients
- She highlighted multiple antibody-drug conjugates (ADCs) currently in clinical trials showing approximately 50% response rates
- Recommendation to refer patients early before administering standard therapies like pegylated liposomal doxorubicin, gemcitabine, or topotecan
- Biomarker Testing
- Essential testing for folate receptor and HER2 expression immediately upon platinum resistance
- Comprehensive molecular testing recommended for all patients
- Early testing enables access to targeted therapies through clinical trials
- Collaborative Care Networks
- Dr Moore advocated for building relationships with trial centers for patient referrals
- Importance of communication between community oncologists and academic centers with open trials
- Focus on preventing exclusion from promising trials due to prior therapy
Notable Insights:
“Reach out early. Once someone’s platinum resistant, make sure they’re tested for folate. Make sure they’re tested for HER2...make sure you’ve got molecular testing done by whatever platform you want to do.”
“Find a local friend that has trials open and just run things by them so we can get patients access to these medications that are actually working.”
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
